The performance of companies tied to the drug's legacy presents a intricate investment landscape. While the initial success generated substantial profits , generic competition have significantly eroded revenue. Investing in associated pharmaceutical firms now requires a discerning assessment of intellectual property safeguards, evolving patient tre